New drug melflufen tested in Real-World setting for Tough-to-Treat myeloma
NCT ID NCT07559799
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is observing 50 patients with relapsed or refractory multiple myeloma who are taking melflufen plus dexamethasone as a later-line treatment. The goal is to see how well the drug controls the disease in routine medical practice, outside of a controlled trial. Researchers will track response rates, side effects, and how long patients live without their cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- melphalan flufenamide (melflufen) plus dexamethasone
- What this could lead to
- If successful, this study could confirm that melflufen helps control advanced multiple myeloma in everyday practice, offering a treatment option for patients who have run out of other choices.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. The drug is already approved, but it may not work for everyone and can cause side effects like low blood counts or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Praxis für interdisziplinäre Onkologie & Hämatologie
RECRUITINGFreiburg im Breisgau, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact